The $150 level has emerged as a focal point in market discussions around Mirum Pharmaceuticals. Morgan Stanley maintains an Overweight rating with a $150 price target, while Leerink Partners raised its target to $154. These targets sit just above the broader Wall Street consensus of roughly $146.50, making $150 a natural round-number milestone that captures both analyst conviction and psychological significance. With the stock currently trading near $114 after more than doubling over the past twelve months, investors are increasingly asking whether this rare-disease biopharmaceutical company can sustain its momentum and break into the $150 range.
Mirum Pharmaceuticals is a commercial-stage biopharmaceutical company headquartered in Foster City, California, focused on developing and commercializing therapies for rare and orphan liver diseases. The company markets three FDA-approved products: LIVMARLI (maralixibat) for cholestatic pruritus in Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC), Cholbam (cholic acid) for bile acid synthesis disorders, and Ctexli (chenodiol) for cerebrotendinous xanthomatosis (CTX).
Mirum achieved positive cash flow from operations in 2025, a significant milestone for a mid-cap biotech. Product revenue grew 55% year-over-year to $521 million in 2025, and management has guided for 2026 net product sales between $660 million and $680 million. The company's market capitalization stands at approximately $6.9 billion, reflecting the market's favorable view of both the existing commercial franchise and the pipeline.
The bull case for MIRM reaching $150 rests heavily on a series of clinical catalysts unfolding throughout 2026. The VISTAS Phase 2b study of volixibat in primary sclerosing cholangitis (PSC) met its primary endpoint, and Mirum plans to pursue a pre-New Drug Application meeting with the FDA in summer 2026, with a potential NDA submission in the second half of the year. PSC currently has no approved therapies in the United States, giving volixibat blockbuster potential if approved.
Additionally, the Phase 2b portion of the AZURE-1 study of brelovitug in chronic hepatitis delta virus (HDV) also met its primary endpoint, with 100% virologic response in the 300 mg once-weekly arm. Topline Phase 3 data is expected in the second half of 2026. Mirum completed enrollment in the EXPAND Phase 3 study of LIVMARLI for additional rare cholestatic liver diseases, with topline data expected in the fourth quarter. The company also acquired zilurgisertib from Incyte for fibrodysplasia ossificans progressiva (FOP), adding another late-stage asset to the pipeline.
Commercial execution remains strong. LIVMARLI sales jumped 69% year-over-year in 2025 to $359 million, and the bile acid replacement franchise (Cholbam and Ctexli) grew 31% to $161 million. Multiple Wall Street analysts, including those at RBC Capital, have described these revenue trends as "strong and durable."
Wall Street sentiment on Mirum Pharmaceuticals is overwhelmingly positive. All 14 analysts covering the stock rate it either a Buy or Strong Buy, with zero Hold or Sell recommendations. The average 12-month price target stands at approximately $146.50, with targets ranging from a low of $125 (JPMorgan Chase) to a high of $185 (H.C. Wainwright).
Recent analyst actions reinforce the bullish narrative. RBC Capital raised its target to $148 in early July 2026, Morgan Stanley maintained its $150 target, and Wolfe Research initiated coverage with a $145 target. The steady upward drift in price targets over the past several months reflects growing confidence in Mirum's pipeline and commercial execution. The $150 level sits comfortably within the range of active analyst estimates, suggesting it is a plausible near-to-medium-term objective rather than an aspirational figure.
From a technical analysis perspective, the $130 level represents the stock's 52-week high and the most immediate resistance zone. MIRM tested this level in recent months but has not yet closed above it on a sustained basis. A decisive breakout above $130 on strong volume would signal the next leg of the uptrend and open a path toward $150. On the downside, the $110-$113 zone has served as reliable support during recent pullbacks, while the psychologically important $100 level aligns with the stock's 200-day moving average region and would represent a critical area to hold during any broader selloff.
Previous major highs and lows show the stock has carved a series of higher lows since early 2025, confirming a well-defined long-term uptrend. The relatively low beta of approximately 0.49 suggests MIRM has not been highly correlated with broader market swings, making its price action more dependent on company-specific catalysts.
Several obstacles could derail the path to $150. Clinical trial outcomes are inherently binary. While early data for volixibat and brelovitug appear promising, Phase 3 results can disappoint. Any regulatory setback — a Complete Response Letter from the FDA or delays in NDA submission timelines — would severely challenge the bull thesis.
Mirum also remains unprofitable on a GAAP basis, with a trailing-twelve-month net loss of roughly $799 million in 2025, partly reflecting acquisition-related charges from the Bluejay Therapeutics deal. While cash flow turned positive operationally, aggressive investment in the pipeline continues to weigh on bottom-line results. Short interest stands at approximately 15% of the public float, indicating a meaningful contingent of investors betting against the stock. Any negative catalyst could trigger significant downward pressure if short sellers are proven correct.
Competition in the rare liver disease space is intensifying. Larger pharmaceutical companies and other biotechs are developing therapies targeting similar indications, and a first-to-market advantage is not guaranteed for every program in Mirum's pipeline.
Navigating the volatility of biotech stocks requires timely, data-driven insights. Tickeron's AI Daily Buy/Sell Signals leverage artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on evolving market conditions, technical behavior, and AI-driven analysis. The platform helps traders identify emerging opportunities, monitor active positions, and adapt to changing market trends with greater efficiency. For investors tracking MIRM's progress toward levels like $150, AI-generated signals can serve as an additional layer of decision-making support.
The $150 price target for Mirum Pharmaceuticals appears realistic but not guaranteed. The company benefits from an expanding commercial portfolio, multiple late-stage pipeline assets with positive early data, and unanimous Wall Street support. Revenue growth has been robust, and the 2026 guidance of $660 million to $680 million in net product sales suggests continued momentum. However, the journey from $114 to $150 requires clearing the $130 resistance zone first, followed by successful Phase 3 readouts and regulatory progress. Investors should monitor the volixibat PSC regulatory pathway, brelovitug Phase 3 results expected in the second half of 2026, and the EXPAND study topline data as the most important near-term catalysts that will determine whether $150 becomes a reality. The balance of evidence tilts favorably, but the binary nature of biotech investing demands a clear-eyed recognition of the risks involved.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, MIRM has been loosely correlated with XERS. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if MIRM jumps, then XERS could also see price increases.
| Ticker / NAME | Correlation To MIRM | 1D Price Change % | ||
|---|---|---|---|---|
| MIRM | 100% | -1.16% | ||
| XERS - MIRM | 45% Loosely correlated | -1.07% | ||
| PCVX - MIRM | 40% Loosely correlated | -1.76% | ||
| FHTX - MIRM | 38% Loosely correlated | -4.34% | ||
| RYTM - MIRM | 38% Loosely correlated | -0.55% | ||
| ACAD - MIRM | 37% Loosely correlated | +0.04% | ||
More | ||||